Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir +/- Ribavirin in the Topaz-I and Topaz-Ii Trials
AuthID
P-00Q-GD2
P-00Q-GD2